Mathilde H.
- Country
- France
- Department
- Maladies du Sang
Research Overview
- Efficacy of Venetoclax Plus Cytarabine Versus Idarubicin Plus Cytarabine in Post-Remission Therapy for Elderly Patients with Acute Myeloid Leukemia
- Phase I/II Evaluation of 177Lu-PentixaTher Radioligand Therapy in Relapsed/Refractory CXCR4-Positive Acute Leukemia
- Phase 1 Multicenter Dose-Escalation Study of Daratumumab with Idarubicin and Cytarabine or CPX-351 in Patients Aged 60+ with Adverse Risk Acute Myeloblastic Leukemia
Data & Insights
Has run more than one trial at 123 of 251 partner sites.
Specializations
Acute Myeloid Leukemia Research
Dedicated to investigating advanced treatments for acute myeloid leukemia (AML), with particular focus on both newly diagnosed and relapsed/refractory cases. Key expertise in treating FLT3-mutated AML and IDH1-mutated AML.
- Novel Therapeutic Combinations
- Age-Specific Treatment Approaches
- Targeted Molecular Therapies
Special interest in developing treatments for elderly patients and those ineligible for intensive chemotherapy.
Acute Lymphoblastic Leukemia Studies
Focuses on innovative treatments for acute lymphoblastic leukemia (ALL), including specialized approaches for Philadelphia chromosome-positive ALL and various age groups.
- Immunotherapeutic Strategies
- Reduced-Intensity Chemotherapy
- Young Adult Treatment Protocols
Expertise in developing treatment protocols for adults aged 18-65 with newly diagnosed ALL.
Specialized Hematologic Conditions
Research encompassing various hematologic disorders including chronic myelogenous leukemia and immune thrombocytopenia. Particular interest in novel therapeutic approaches and immunological interventions.
- Advanced Phase Leukemias
- Bleeding Disorders
- Immunotherapy Applications
Focus on developing targeted treatments for complex hematological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.